SK biopharmaceuticals
SK Biopharmaceuticals is a global pioneer in biotech innovation, focusing on the development, research, and commercialization of new drugs, especially in CNS disorders and oncology. The company has independently developed cenobamate, an anti-seizure medication, and discovered solriamfetol, a treatment for sleep disorders. It aims to expand into emerging markets and new therapeutic modalities, striving to become a leading 'Big Biotech'.
Industries
Nr. of Employees
large (251-1000)
SK biopharmaceuticals
221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Patents
Compound having oxadiazole and pharmaceutical composition containing the same
US-12145914-B2
View Details
Compound having oxadiazole and pharmaceutical composition containing the same
US-12145914-B2
View DetailsProducts
Cenobamate (anti-seizure medication)
Small-molecule anti-seizure therapeutic developed through discovery, clinical trials and regulatory approval for treatment of partial-onset seizures and other epilepsy indications.
Solriamfetol (treatment for sleep disorder)
Small-molecule therapeutic discovered and advanced through early clinical development for excessive daytime sleepiness and related sleep disorders; rights licensed to external developer for global commercialization outside select Asian markets.
Cenobamate (anti-seizure medication)
Small-molecule anti-seizure therapeutic developed through discovery, clinical trials and regulatory approval for treatment of partial-onset seizures and other epilepsy indications.
Solriamfetol (treatment for sleep disorder)
Small-molecule therapeutic discovered and advanced through early clinical development for excessive daytime sleepiness and related sleep disorders; rights licensed to external developer for global commercialization outside select Asian markets.
Services
Structuring and executing research collaborations and license agreements for development and commercialization of drug candidates.
End-to-end management of clinical programs and regulatory filings across multiple jurisdictions.
Collaborative research agreements and isotope sourcing arrangements to develop radiopharmaceutical therapeutics and theranostic candidates.
Discovery-stage programs and platform research focused on targeted protein degradation conducted through a specialized discovery entity.
Management of commercial drug-substance supply agreements and provision of process validation preparation support to enable manufacturing readiness.
Implementation and contracting of enterprise cloud services and software to support global operations and digital workflows.
Structuring and executing research collaborations and license agreements for development and commercialization of drug candidates.
End-to-end management of clinical programs and regulatory filings across multiple jurisdictions.
Collaborative research agreements and isotope sourcing arrangements to develop radiopharmaceutical therapeutics and theranostic candidates.
Discovery-stage programs and platform research focused on targeted protein degradation conducted through a specialized discovery entity.
Management of commercial drug-substance supply agreements and provision of process validation preparation support to enable manufacturing readiness.
Implementation and contracting of enterprise cloud services and software to support global operations and digital workflows.
Expertise Areas
- Clinical trial management
- Central nervous system (CNS) drug development
- Oncology drug development
- Radiopharmaceutical therapy development
Key Technologies
- Small-molecule drug discovery
- Targeted protein degradation (TPD)
- Radiopharmaceuticals and theranostics
- Preclinical animal models
News & Updates
Press release about collaboration with ProEn Therapeutics for radiopharmaceuticals.
Press release about Eurofarma submitting NDA for cenobamate in Brazil.
Press release about licensing agreement with Full-Life Technologies.
Press release about collaboration with ProEn Therapeutics for radiopharmaceuticals.
Press release about Eurofarma submitting NDA for cenobamate in Brazil.
Press release about licensing agreement with Full-Life Technologies.